| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 5.54▲ | 5.53▲ | 5.62▲ | 5.51▲ | 7.07▼ |
| MA10 | 5.50▲ | 5.62▲ | 5.62▲ | 6.02▼ | 7.58▼ |
| MA20 | 5.49▲ | 5.62▲ | 5.51▲ | 7.22▼ | 7.16▼ |
| MA50 | 5.62▲ | 5.54▲ | 5.56▲ | 7.64▼ | 6.08▼ |
| MA100 | 5.62▲ | 5.67▼ | 6.81▼ | 7.06▼ | 8.68▼ |
| MA200 | 5.52▲ | 6.91▼ | 8.01▼ | 6.25▼ | 25.01▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.025▲ | -0.017▼ | 0.028▲ | -0.245▼ | -0.223▼ |
| RSI | 64.228▲ | 54.048▲ | 51.366▲ | 33.632▼ | 43.228▼ |
| STOCH | 79.167 | 21.817 | 50.326 | 11.047▼ | 36.222 |
| WILL %R | 0.000▲ | -48.889 | -37.288 | -84.158▼ | -89.316▼ |
| CCI | 231.514▲ | -22.709 | 3.805 | -59.503 | -123.490▼ |
|
Thursday, March 26, 2026 04:01 AM
Karyopharm Therapeutics faces heightened uncertainty after mixed phase 3 SENTRY results for selinexor in myelofibrosis. Learn more about KPTI stock here.
|
|
Tuesday, March 24, 2026 08:50 AM
Karyopharm Therapeutics (NASDAQ:KPTI) reported top-line results from its phase III SENTRY trial evaluating selinexor in combination with ruxolitinib in JAK inhibitor-naive (frontline) myelofibrosis, h ...
|
|
Tuesday, March 24, 2026 07:36 AM
Karyopharm Therapeutics (KPTI) stock fell 12.71% after announcing a $30M private placement with RA Capital, sparking investor dilution concerns.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 01/04/26 | 5.75 | 5.86 | 5.41 | 5.64 | 303,852 |
| 31/03/26 | 5.31 | 5.75 | 5.31 | 5.57 | 505,537 |
| 30/03/26 | 5.40 | 5.57 | 5.25 | 5.30 | 829,735 |
| 27/03/26 | 5.51 | 5.77 | 5.40 | 5.48 | 847,250 |
| 26/03/26 | 5.075 | 5.61 | 5.00 | 5.57 | 4,207,983 |
| 25/03/26 | 5.36 | 5.71 | 5.095 | 5.21 | 1,655,277 |
| 24/03/26 | 6.025 | 6.50 | 5.14 | 5.44 | 17,851,885 |
| 23/03/26 | 7.34 | 7.578 | 6.57 | 6.66 | 967,060 |
| 20/03/26 | 7.76 | 9.04 | 7.435 | 7.63 | 1,496,158 |
| 19/03/26 | 8.33 | 8.6151 | 7.73 | 7.73 | 759,748 |
|
|
||||
|
|
||||
|
|